Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)

• Status: Unknown status
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Genetic factors of an individual patient may have an impact on Ranibizumab (Lucentis) treatment outcome in patients with Wet Age-Related Macular Degeneration (AMD).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Russian Academy of Medical Sciences
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Patients must be at least 50 years old

• Neovascular age-related macular degeneration

• CNV in the central part of the retina (macular is involved)

• Active CNM (seen on fundus fluorescein angiography)

• CNV activity is on one of the following: sub-retinal hemorrhage, sub-retinal lipid, documented loss of 3 lines of vision during last 3 months

• Visual acuity of between 20/40 and 20/300 (ETDRS)

Exclusion Criteria:

• Patients under 50 years old

• Patients with CNM not caused by AMD

• Patients physically unable to tolerate intravenous fluorescein angiography

• Patients with medically uncontrolled glaucoma

• Patients with history of bronchial asthma, thrombophlebitis, polyvalent allergy, cancer

• Any intraocular surgery within 3 months in the study eye

• Prior retinal or vitreous surgery including vitrectomy or scleral buckling

• Any significant ocular disease other than AMD that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome

• Individuals with physical or mental disabilities that prevent accurate vision testing

• History of any laser treatment of CNV in study eye (laser photocoagulation or prior photodynamic therapy), or anti-VEGF (ranibizumab or bevacizumab) in the past 2 years in the study eye.